New blood marker could improve prostate cancer survival predictions

Researchers have identified a combination of two biomarkers—thymidine kinase 1 and PSA—that may predict survival outcomes in prostate cancer patients more accurately than PSA alone. The finding could help oncologists identify high-risk patients earlier and tailor treatment strategies, potentially reducing mortality and improving resource allocation in cancer care.

Originaltitel: Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer